Polr3h^em2Cfe

CRISPR/Cas9 technology generated an A to G change at position 149 (c.149A>G) resulting in an aspartate to glycine substitution at residue 50 (p.D50G). In addition, a TaqalphaI site was introduced. This a pathogenic variant identified in human primary ovarian insufficiency. (J:290735)